Holen Sie sich die Stockscreener-App
31.33
0.51%
-0.16
Vorhandelsmarkt:
31.97
0.64
+2.04%
Schlusskurs vom Vortag:
$31.49
Offen:
$31.59
24-Stunden-Volumen:
796.72K
Relative Volume:
0.66
Marktkapitalisierung:
$2.40B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-11.43
EPS:
-2.74
Netto-Cashflow:
$-156.53M
1W Leistung:
-0.48%
1M Leistung:
-2.25%
6M Leistung:
-20.06%
1J Leistung:
-27.34%
1-Tages-Spanne:
$31.11
$31.98
1-Wochen-Bereich:
$31.11
$32.72
52-Wochen-Spanne:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Vergleichen Sie XENE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
31.33 | 2.42B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Bank of New York Mellon Corp - Defense World
How Xenon Pharmaceuticals Inc. stock performs during market volatilityFree Access to Community - Newser
Xenon Pharmaceuticals Inc. Stock Analysis and ForecastFree Bull & Bear Market Updates - jammulinksnews.com
Is Xenon Pharmaceuticals Inc. a good long term investmentFree Stock Selection - jammulinksnews.com
What drives Xenon Pharmaceuticals Inc. stock priceHigh-octane financial growth - jammulinksnews.com
What analysts say about Xenon Pharmaceuticals Inc. stockRapid profit acceleration - jammulinksnews.com
Mutual of America Capital Management LLC Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Should I buy Xenon Pharmaceuticals Inc. stock before earningsFree Smart Money Stock Analysis - Newser
(XENE) Investment Analysis and Advice - news.stocktradersdaily.com
Teacher Retirement System of Texas Reduces Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Why Xenon Pharmaceuticals Inc. stock attracts strong analyst attentionReliable High Profit Alerts - Newser
What makes Xenon Pharmaceuticals Inc. stock price move sharplyHigh Yield Opportunities - Newser
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely - Yahoo Finance
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
How to Take Advantage of moves in (XENE) - news.stocktradersdaily.com
CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN
Xenon Appoints CEO Ian Mortimer as Interim CFO - The Globe and Mail
XENE CEO Named Interim CFO After Sherry Aulin Resigns | XENE SEC FilingForm 8-K - Stock Titan
Xenon Pharmaceuticals Inc.(NasdaqGM:XENE) added to Russell Small Cap Comp Growth Index - MarketScreener
Xenon Pharmaceuticals: Riding the Russell Wave to Institutional Inflows and Clinical Milestones? - AInvest
Xenon Joins the Russell 3000® and Russell 2000® Indexes - The Manila Times
Xenon Pharmaceuticals added to Russell 3000 and 2000 indexes - Investing.com India
Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - Quiver Quantitative
Xenon Pharmaceuticals added to Russell 3000 and 2000 indexes By Investing.com - Investing.com South Africa
Xenon Pharmaceuticals Announces Equity Inducement Grants to New Employees - TipRanks
Is Xenon Pharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer - The Globe and Mail
Long Term Trading Analysis for (XENE) - news.stocktradersdaily.com
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of “Buy” from Analysts - Defense World
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $57 - 富途牛牛
Xenon Pharmaceuticals price target raised to $57 from $55 at RBC Capital - Investing.com Canada
RBC Raises Price Target on Xenon Pharmaceuticals to $57 From $55, Keeps Outperform, Speculative Risk - MarketScreener
Cantor Fitzgerald Estimates XENE FY2026 Earnings - MarketBeat
Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Brokers Set Expectations for XENE FY2026 Earnings - Defense World
Xenon Pharmaceuticals at Goldman Sachs Conference: Strategic Clinical Advances By Investing.com - Investing.com Canada
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):